{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T22:05:14Z","timestamp":1781906714474,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.vaccine.2020.03.008","type":"journal-article","created":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T08:34:27Z","timestamp":1584174867000},"page":"3313-3320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Comparison of purified psoralen-inactivated and formalin-inactivated dengue vaccines in mice and nonhuman primates"],"prefix":"10.1016","volume":"38","author":[{"given":"Appavu K.","family":"Sundaram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ewing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Blevins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaodong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Sink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Lassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanakatte","family":"Raviprakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Defang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7446","key":"10.1016\/j.vaccine.2020.03.008_b0005","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"issue":"Suppl 10","key":"10.1016\/j.vaccine.2020.03.008_b0010","first-page":"S123","article-title":"Vaccine update: recent progress with novel vaccines, and new approaches to safety monitoring and vaccine shortage","volume":"58","author":"Ndaya-Oloo","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.vaccine.2020.03.008_b0015","first-page":"299","article-title":"Epidemiology of dengue: past, present and future prospects","volume":"5","author":"Murray","year":"2013","journal-title":"Clin Epidemiol"},{"issue":"14","key":"10.1016\/j.vaccine.2020.03.008_b0020","doi-asserted-by":"crossref","first-page":"6927","DOI":"10.1128\/JVI.02724-07","article-title":"A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus","volume":"82","author":"Raviprakash","year":"2008","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2020.03.008_b0025","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029371","article-title":"Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? the path to a dengue vaccine: learning from human natural dengue infection studies and vaccine trials","volume":"10","author":"de Silva","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"29","key":"10.1016\/j.vaccine.2020.03.008_b0030","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1016\/j.vaccine.2015.05.010","article-title":"The dengue vaccine pipeline: Implications for the future of dengue control","volume":"33","author":"Schwartz","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.008_b0035","unstructured":"WHO Advises Dengvaxia be used in people previously infected with dengue. 11\/13\/2018]; Available from: http:\/\/www.who.int\/immunization\/diseases\/dengue\/q_and_a_dengue_vaccine_dengvaxia\/en\/."},{"issue":"2","key":"10.1016\/j.vaccine.2020.03.008_b0040","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2217\/cer-2016-0045","article-title":"CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety","volume":"6","author":"Godoi","year":"2017","journal-title":"J Comp Eff Res"},{"issue":"38","key":"10.1016\/j.vaccine.2020.03.008_b0045","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1016\/j.vaccine.2016.06.082","article-title":"Assessing dengue vaccination impact: Model challenges and future directions","volume":"34","author":"Recker","year":"2016","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2020.03.008_b0050","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.4161\/hv.25602","article-title":"Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice","volume":"9","author":"Raviprakash","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2020.03.008_b0055","doi-asserted-by":"crossref","first-page":"454","DOI":"10.4269\/ajtmh.14-0819","article-title":"Safety and immunogenicity of a dengue virus serotype-1 purified-inactivated vaccine: results of a phase 1 clinical trial","volume":"93","author":"Martinez","year":"2015","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"10.1016\/j.vaccine.2020.03.008_b0060","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4269\/ajtmh.16-0634","article-title":"Phase 1 randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults in the United States","volume":"96","author":"Schmidt","year":"2017","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.vaccine.2020.03.008_b0065","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.4269\/ajtmh.17-0627","article-title":"Phase I randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults from puerto rico","volume":"98","author":"Diaz","year":"2018","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.vaccine.2020.03.008_b0070","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0021-9258(18)57104-0","article-title":"The reaction of formaldehyde with proteins; demonstration of intermolecular cross-linking by means of osmotic pressure measurements","volume":"177","author":"Fraenkel-Conrat","year":"1949","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.vaccine.2020.03.008_b0075","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0002-9440(10)65461-2","article-title":"A high frequency of sequence alterations is due to formalin fixation of archival specimens","volume":"155","author":"Williams","year":"1999","journal-title":"Am J Pathol"},{"issue":"4 Suppl 11","key":"10.1016\/j.vaccine.2020.03.008_b0080","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0037-1963(01)90118-0","article-title":"Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma","volume":"38","author":"Wollowitz","year":"2001","journal-title":"Semin Hematol"},{"issue":"2","key":"10.1016\/j.vaccine.2020.03.008_b0085","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1099\/0022-1317-40-2-345","article-title":"Photochemical inactivation of DNA and RNA viruses by psoralen derivatives","volume":"40","author":"Hanson","year":"1978","journal-title":"J Gen Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.03.008_b0090","first-page":"7","article-title":"Photochemical inactivation of viruses with psoralens: an overview","volume":"18","author":"Hanson","year":"1992","journal-title":"Blood Cells"},{"issue":"6","key":"10.1016\/j.vaccine.2020.03.008_b0095","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/infdis\/174.6.1176","article-title":"Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys","volume":"174","author":"Putnak","year":"1996","journal-title":"J Infect Dis"},{"issue":"32","key":"10.1016\/j.vaccine.2020.03.008_b0100","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1016\/j.vaccine.2019.06.083","article-title":"Enhanced immunogenicity and protective efficacy of a tetravalent dengue DNA vaccine using electroporation and intradermal delivery","volume":"37","author":"Williams","year":"2019","journal-title":"Vaccine"},{"issue":"50","key":"10.1016\/j.vaccine.2020.03.008_b0105","doi-asserted-by":"crossref","first-page":"7728","DOI":"10.1016\/j.vaccine.2018.10.072","article-title":"Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature","volume":"36","author":"Boigard","year":"2018","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2020.03.008_b0110","doi-asserted-by":"crossref","first-page":"698","DOI":"10.4269\/ajtmh.14-0268","article-title":"An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques","volume":"92","author":"Fernandez","year":"2015","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.vaccine.2020.03.008_b0115","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4269\/ajtmh.1996.55.504","article-title":"Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells","volume":"55","author":"Putnak","year":"1996","journal-title":"Am J Trop Med Hyg"},{"issue":"20","key":"10.1016\/j.vaccine.2020.03.008_b0120","doi-asserted-by":"crossref","first-page":"11955","DOI":"10.1128\/JVI.01809-14","article-title":"Effect of formaldehyde inactivation on poliovirus","volume":"88","author":"Wilton","year":"2014","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2020.03.008_b0125","first-page":"979","article-title":"Inactivation of poliovirus by formaldehyde: theoretical and practical aspects","volume":"17","author":"Gard","year":"1957","journal-title":"Bull World Health Organ"},{"issue":"2","key":"10.1016\/j.vaccine.2020.03.008_b0130","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1128\/CVI.00353-09","article-title":"Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice","volume":"17","author":"Maves","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"15","key":"10.1016\/j.vaccine.2020.03.008_b0135","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1016\/j.vaccine.2011.01.077","article-title":"Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys","volume":"29","author":"Maves","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.008_b0140","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jviromet.2016.04.023","article-title":"Cellufine sulfate column chromatography as a simple, rapid, and effective method to purify dengue virus","volume":"234","author":"Kanlaya","year":"2016","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2020.03.008_b0145","unstructured":"Purification of Influenza A\/H1N1 using Capto Core 700. GE Healthcare Life Sciences Application Note 29-0003-34 AA Vaccines; Available from: http:\/\/www.processdevelopmentforum.com\/files\/articles\/App_note_29_0003.pdf."},{"issue":"4","key":"10.1016\/j.vaccine.2020.03.008_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007721","article-title":"Detection of post-vaccination enhanced dengue virus infection in macaques: An improved model for early assessment of dengue vaccines","volume":"15","author":"Borges","year":"2019","journal-title":"PLoS Pathog"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20303510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20303510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:41:56Z","timestamp":1759401716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20303510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":30,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0264410X20303510"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.008","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of purified psoralen-inactivated and formalin-inactivated dengue vaccines in mice and nonhuman primates","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}